Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis
Open Access
- 22 April 2024
- journal article
- research article
- Published by BMJ in BMJ Global Health
- Vol. 9 (4) , e014630
Abstract
Background Research and development (R&D) of new drugs and regimens against tuberculosis (TB) is evolving to meet new challenges and face limited investments in the sector. To effectively improve and fill existing gaps, researchers and trialists should engage a broad spectrum of stakeholders. With this study, we aim to map the interests in TB R&D raised by the main stakeholders in the TB field. Methods We conducted semistructured, short interviews to gather insight and viewpoints on innovation on TB drugs and regimens R&D of policy-makers, national TB programme officers, donors, funders, non-governmental organisations and research institutions. A composite measure of the relevance of topics that emerged was computed by implementing different models considering the importance for researchers and the urgency to implement those changes during the trial, the number of citations each topic received, and the maximum value of the influence of stakeholders who had raised the topic. Results 50 stakeholders, out of 56 identified, were interviewed and almost half were policy-makers and governmental institutions. Several stakeholders highlighted the importance of disseminating information about clinical trials’ methodology and emerging preliminary results, followed by the need to pursue early discussion around access and pricing of safe and effective TB innovations, although different categories of stakeholders prioritised different topics. Using different methods for ranking topics, the results remained almost unchanged. Notably, post-trial operational research ranked higher in models with higher weight for the parameter considering the number of citations. Conclusion Researchers and research consortia embarking on phase 2 and 3 clinical trials should consider a broad set of elements when planning and designing trials’ protocols, all aiming at lowering the price and improving access to emerging TB innovations, besides meeting regulatory criteria. This can only be achieved by consulting and engaging relevant stakeholders in the discussion.Keywords
Funding Information
- Innovative Medicines Initiative (101007873, UNITE4TB)
This publication has 33 references indexed in Scilit:
- Scientific advances and the end of tuberculosis: a report from the Lancet Commission on TuberculosisThe Lancet, 2023
- Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trialThe Lancet Global Health, 2022
- Revisiting the issue of access to medicines in Africa: Challenges and recommendationsPublic Health Challenges, 2022
- Master protocols: New directions in drug discoveryContemporary Clinical Trials Communications, 2020
- Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issuesNature Reviews Microbiology, 2019
- The New Drug Conditional Approval Process in China: Challenges and OpportunitiesClinical Therapeutics, 2017
- Making norms to tackle global challenges: The role of Intergovernmental OrganisationsResearch Policy, 2017
- Tackling the Tuberculosis Epidemic in sub-Saharan Africa – unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024International Journal of Infectious Diseases, 2015
- FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant TuberculosisNew England Journal of Medicine, 2014
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011